# A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

> **NCT02279719** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** BBI608
- **DRUG:** BBI503
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02279719
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2019-07
- **Final completion:** 2019-10
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279719, "A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02279719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*